Sachs Associates’ Post

Most Comprehensive Molecular KRAS Portrait to Date Can Inform Pancreatic Cancer Treatment Response Researchers published two separate articles “Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers,” and “Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer,” published in Science, say they have developed the most comprehensive molecular portrait of the oncogene KRAS and how its activities affect outcomes for pancreatic cancer. The research could help clinicians to select more targeted treatment options for pancreatic cancer patients. Because less than 40% of pancreatic cancers respond to treatment with KRAS inhibitors, if we can establish molecular markers to predict which patients will respond, we can better provide them with specific treatments, which should improve their outcomes. While KRAS is one of the most commonly mutated genes across all cancer types, and is present in more than 90% pancreatic cancers, its mechanisms for promoting cancer growth are still largely unknown. This knowledge gap was the basis of the new findings from the research team. In what they describe as the most detailed analysis of KRAS to date, the investigators showed that the molecular pathway most responsible for the cancer-promoting functions of the oncogene is highly dependent on the ERK protein. ERK regulates which genes are expressed and which proteins are active. The ERK protein has been broadly studied since it is known to be a significant player in the function of KRAS, but its role has remained unclear. Two KRAS inhibitors have been approved for treatment to date and, since it is such a prevalent and promising target, there are a number of KRAS targeting drugs moving through clinical trials. The investigators of the earlier studies showed that the MYC oncogene can cause resistance to KRAS therapies. The papers published in Science established that MYC is a significant component of how both KRAS and ERK support cancer growth and that it is also a driver of therapy resistance to KRAS and ERK targeting therapies. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

🌟 Revolution in Cancer Treatment: The Potential of Antibody-Drug Conjugates (ADCs) 🌟 In #oncology, we are at the dawn of a new era marked by the rapid development and application of antibody-drug conjugates (#ADCs). These innovative therapies combine the precision targeting of antibodies with the power of chemotherapy agents to directly attack #cancer cells while largely sparing healthy tissue. 💪 This technology promises a revolution in the treatment of various cancers by enhancing the efficacy of therapy while minimizing side effects. 💰 The market potential for ADCs is tremendous: experts predict a doubling of the global revenue to nearly $20 billion by 2028. These figures reflect not only the financial significance for #pharma companies but also the potential impact on patient care. Companies like Daiichi Sankyo, Inc., AstraZeneca, and BioNTech SE are at the forefront of this development. Daiichi-Sankyo recently announced a significant investment of one billion euros to expand their facility in Upper Bavaria for the further development and production of their ADC-based cancer drugs, including the fast-growing ADC #Enhertu. Enhertu, a frontrunner in ADC therapy, is already being used successfully in the treatment of breast, lung, and stomach cancer, generating revenues of almost $2.6 billion last year alone. BioNTech is also actively engaged in ADC research through its recent collaboration with DualityBio and MediLink, to develop and advance innovative cancer therapies. The U.S. health authorities have granted two ADC product candidates from BioNTech Breakthrough Therapy status, highlighting the importance of this research and enabling accelerated approval. 🌏 👨👩👧👧 These developments are not just a testament to progress in medical research but also a commitment to improving the #qualityoflive for patients worldwide. The investments and achievements of these companies underscore the immense potential of ADC technology to reshape the future of cancer treatment. #Oncology #CancerResearch #ADCs #PharmaInnovation

#AI Firm Lantern Pharma (NASDAQ: LTRN) Receives Regulatory Approval to Expand Harmonic™ Clinical Trial Led By Dr. Yashushi Goto At The National Cancer Center of #Japan ***Approximately 33% of all non-small cell #lungcancer patients in #EastAsia are never #smokers – a growing and unaddressed patient population. ****According to the American Cancer Society, lung cancer is the second leading cause of cancer in the US, with over 200,000 patients diagnosed annually. Historically, #neversmokers with #NSCLC make up about 15-20% of all lung cancer patients, representing an approximate annual market potential of $1.5 to $2.0 billion. *****NSCLC presents differently in never smokers, which are defined by the #CDC as a person who has smoked 100 #cigarettes or less in their life, compared to smokers. These differences are believed to be due to a higher percentage of genetic mutations in a family of cancer-promoting genes called Tyrosine Kinases (TK). Changes in TK genes, such as EGFR, ALK, ROS and MET, can contribute to the development of healthy cells into cancer cells, leading to tumor formation and growth. LP-300’s intended mechanism is to work together with chemotherapy by strongly interacting in the TK gene pathways, interrupting their activity to slow or prevent tumor growth and spread. #smoking #cancer #lungcancer #artificialintelligence #biotech #cancerresearch

I'm excited to share some key findings from the Global Oncology Trends 2024: Outlook to 2028 by the IQVIA Institute: - Cancer incidence is projected to rise significantly through 2050, notably in lower-income countries, with a potential increase of over 12 million new cases annually to 32 million. - Global spending on cancer medicine reached $223 billion in 2023, marking a $25 billion increase from 2022, and is estimated to hit $409 billion by 2028. - 25 oncology novel active substances (NASs) were introduced globally in 2023, adding up to 193 since 2014, although there are substantial geographic disparities in their availability. - In 2023, over 2,000 new oncology clinical trials began, showcasing innovative modalities like cell and gene therapies, antibody-drug conjugates, multispecific antibodies, and radioligand therapies, offering significant promise for cancer treatment. - Despite a 9% annual increase in cancer treatments since 2019, the delivery of novel therapies to patients varies due to differences in biomarker testing rates, adoption of new treatments, and insufficient infrastructure capacity for the most advanced therapies. Stay informed about the latest trends and developments shaping the landscape of cancer treatment and research. #IQVIA #CancerResearch #Oncology #HealthcareTrends #DataAndAnalytics #Patients #DataStrategy Murray Aitken Kim Mehle Michael Kleinrock Jamie Pritchett Aziz Mallik Eliza Silvester Abir Yamak, Ph.D. Carmen Sivakumaren, PhD Eric E. Bayir, MSc, MBA Gonzalo Lemus Terry Shea Inderpreet Kambo (DDS, MS) Ankur Chopra David Vento, MBA Matthew Smith Indraneel Mukherjee Leah Magid Herbert Yash Dave James Noll Greg Plante Charles Vizzini Jun G. Kelley Coalier, MS, MBA Valerie Eng Angela Donato Daniel Feld, MBA, MPH Aakansha Nangarlia, PhD Chuchih Shih Betsy Benning Laila R. Gary Minarich

In January 2022, a research team from UH Seidman Cancer Center and Case Western Reserve University published a groundbreaking report detailing a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers. The new B-cell activating factor (BAFF) CAR T product, developed by UH Seidman and CWRU scientist Reshmi Parameswaran, MS, PhD, and colleagues, binds specifically to each of three receptors instead of one, providing more therapeutic options and guarding against the problem of antigen escape currently found in CAR T therapies with a single target. Experimental results showed that the BAFF CAR T is effective at killing multiple B-cell cancers. Now just two short years later, these crucial findings have reached an important new phase: A Phase I BAFF CAR T clinical trial for patients with relapsed and refractory multiple myeloma is now underway at UH Seidman Cancer Center, led by hematologist-oncologist Leland Metheny, MD. He says in the two years since the foundational pre-clinical work was completed, the team has shown that it’s feasible to manufacture BAFF CAR T-cells for human subjects. The innovation is introducing genes into the T-cells via the process of electroporation in the Wesley Center for Immunotherapy. This study is being done through an agreement between University Hospitals and Luminary Therapeutics, a biotech start-up based in Minneapolis. Luminary is an allogeneic CAR T drug development company with programs addressing B-cell malignancies, autoimmune disease and solid tumors. Dr. Metheny says he’s excited about the potential for the patients he treats. “There is a persistent need for development of new, effective therapies for treatment of myeloma,” he says. Therapy with CAR T-cells has demonstrated activity against refractory myeloma. Through this trial, we are assessing if BAFF CAR T-cells can become another strategy for our patients with refractory disease.” Read more at https://lnkd.in/gTxW7hzq #multiplemyeloma #CAR T #BAFF CAR T #clinicaltrials #patientsfirst

🚀 ** BREAKING NEWS Major Advancement in Liver Cancer Treatment Announced** G1 Therapeutics, Inc. and Pepper Bio have revealed a promising new liver cancer drug, Lerociclib, representing a significant breakthrough in combating this challenging form of cancer. **Understanding the Impact:** Liver cancer presents significant hurdles due to its aggressive nature and limited treatment options. Lerociclib offers renewed hope by targeting specific mechanisms driving cancer progression, potentially revolutionizing how we manage the disease. **Key Highlights:** ✅ - Precision Medicine: Lerociclib employs advanced omics technologies to pinpoint and target precise molecular pathways implicated in liver cancer, enhancing therapeutic effectiveness while minimizing side effects. ✅ - Collaborative Innovation: The partnership between G1 Therapeutics and Pepper Bio highlights the power of interdisciplinary collaboration in driving medical advancements. By combining expertise in drug development and omics analysis, they've accelerated the translation of scientific findings into tangible patient benefits. ✅ - Hope for Patients: Lerociclib represents more than just a drug; it symbolizes extended survival, improved quality of life, and the possibility of overcoming a formidable disease for liver cancer patients. **Looking Ahead:** As Lerociclib progresses through clinical trials and regulatory processes, its potential to reshape liver cancer treatment is significant. This milestone serves as a catalyst for continued investment and innovation in oncology research, fostering optimism for future breakthroughs. **Final Thoughts:** The unveiling of Lerociclib underscores our commitment to scientific excellence and improving patient outcomes. It demonstrates the transformative impact of collaboration, innovation, and perseverance in addressing healthcare challenges. Stay tuned for updates on Lerociclib and its potential to make a profound difference in the lives of millions worldwide. Read more here: https://lnkd.in/dVHaj54P #LiverCancer #MedicalInnovation #PrecisionMedicine #Oncology #Hope #HealthcareAdvancements

🌟 Team BPGbio at AACR 2024 in San Diego 🌟 This week, the BPGbio team (Michael Kiebish, Ph.D. Anjan G. Thakurta Alex Batrouni, Ph.D. & Nischal M.) is at the AACR Annual Meeting in beautiful San Diego, a gathering of the world's most distinguished minds in cancer research. 🔬 Presenting the success from our NAi Interrogative Biology platform: our latest findings on 4 areas of our oncology research and clinical development. 1. New data supports the dual functionality of BPM31510, showcasing not only its direct tumor cell-killing capabilities but also its potential role in modulating the immune system through the lens of tumor immunology and metabolism. 2. NAi Platform and Deep Learning in Drug Development: BPGbio's NAi Platform, enhanced with deep learning algorithms, has been applied to BRG399, a novel pan-cancer drug candidate. This combination significantly boosts drug development efficiency by enabling rapid in silico predictions of anti-cancer efficacy, thereby reducing the need for early-stage, resource-heavy preclinical experiments. 3. pstateDx™ Test Validation in Mexico: A study conducted in Mexico has further validated the effectiveness of BPGbio’s prostate cancer biomarker test, pstateDx™, which was identified through the NAi Platform. This validation in an independent population underscores the test's utility in diagnosing prostate cancer. 4. Identification of UBE2M as a Cancer Therapy Target: New research has validated UBE2M as a novel, potential therapeutic target for cancer, discovered through the innovative use of BPGbio's NAi Platform. This discovery opens up new avenues for cancer treatment strategies. These findings collectively demonstrate the capabilities of BPGbio's NAi Platform in enhancing cancer drug development and discovery, ultimately aiming to improve patient outcomes in cancer care. #cancerresearch #microtumorenvironment #AIplatform #AIdrugdiscovery #oncology #AACR #AACR2024 #Prostatecancer #glioblastoma #Pancreaticcancer #UBE2M

Did you know? 90% of cancer deaths result from metastasis? . . Introducing Mestastop Solutions: Unravelling Metastasis In 2020, nearly 10 million lives succumbed to cancer globally, with 90% lost to the relentless grip of metastasis—the silent invader. Meet Mestastop Solutions, a pioneer in the fight against metastasis, aiming to reshape the narrative of cancer outcomes. Here's why our journey is a beacon of hope.......... The metastasis enigma: Despite advancements, 90% of cancer deaths result from metastasis. Shockingly, only one out of 215+ approved cancer drugs addresses this perilous stage! Mestastop is on a mission to change that. Our Revolutionary Approach: Mestastop introduces three proprietary platforms— 🔹 METAssay® 🔹 METVivo® 🔹 METSCAN® —bridging in vitro and in vivo realms. These platforms, coupled with translational validation, unravel the complexities of metastasis, offering pathways for drug discovery and predictive diagnostics. We are addressing 2 critical problems: ✅ Problem 1 – Drug Discovery: 90% of cancer deaths are due to metastasis No drugs to delay metastasis Current drugs only tackle tumour growth ✅ Problem 2 – Clinical Trials: Identifying high-risk patients for trials Lymph Node positivity falls short Our Solution: METFIND® - Integrating Wet Lab Data with Machine Learning Our Vision: Unravel Metastasis Our Mission: Build Novel Translational Models Welcome to Mestastop's journey, where innovation meets compassion. Together, let's unravel metastasis and usher in a new era of drug discovery and companion diagnostics. #metastaticbreastcancer #metastasis #drugdevelopment #cancerdiagnostics #cancertreatment #drugrepurposing #drugdiscovery

Precision Oncology: PROTACs Targeting Transcription Factors Transcription factors (TFs) are crucial in cancer progression, yet many lack druggable pockets, making direct targeting difficult. Instead, targeting TF coregulators, like the mammalian switch/sucrose non-fermentable (mSWI/SNF) chromatin remodeling complex, has emerged as a promising strategy. In castration-resistant prostate cancer (CRPC), inhibiting the mSWI/SNF disrupts key TF signaling. A recent study by a research team led by Prof. Arul Chinnaiyan at the University of Michigan - Ann Arbor , expands on these findings, identifying the mSWI/SNF complex as a therapeutic vulnerability in POU2F3 (POU domain class 2 transcription factor 3; also known as OCT-11)- driven small cell lung cancer (SCLC) and POU2AF1-dependent B cell malignancies. The orally bioavailable mSWI/SNF ATPase degrader, AU-24118, shows significant anti-tumor activity in preclinical models of SCLC and multiple myeloma (MM) without toxicity. AU-24118 is a PROTAC (Proteolysis Targeting Chimera) that targets the ATPase subunits SMARCA2 and SMARCA4 of the mSWI/SNF chromatin remodeling complex, leading to their degradation and disruption of the complex’s function. The findings of this study suggest that targeting mSWI/SNF could enhance cancer treatment, particularly in neuroendocrine prostate cancer (NEPC) and other malignancies. Overall, this study positions mSWI/SNF ATPase degraders as promising candidates for clinical testing, reinforcing the value of targeting TF coregulators in oncology. Link to the article: https://lnkd.in/gm3kQ_QV #cancertherapy #precisiononcology #oncology #protac #targetedproteindegradation #prostatecancer #multiplemyeloma Lanbo Xiao Yuanyuan Qiao Eleanor Young Rahul Mannan Somnath Mahapatra Esther Redín Resano Hanbyul Cho Malathi Kandarpa Sanjana Eyunni Yang Zheng. Chandrasekhar Abbineni Susanta Samajdar Murali Ramachandra moshe talpaz Abhijit Parolia Arul Chinnaiyan

#Procurement Services for Biospecimens in Cancer Research At The Biospecimen Private Ltd, we take this opportunity to reaffirm our dedication to supporting scientists and advancing research in the field of lung cancer. We have been at the forefront of facilitating scientific endeavors by supplying a diverse range of human biospecimens from individuals with various cancer types, including lung cancer. At The Biospecimen, we are fully equipped to bolster cancer research efforts. Contact us to procure lung cancer biospecimens accompanied by relevant data and discover the advantages of collaborating directly with us. We facilitate #BiosampleProcurement through an extensive network of affiliated hospitals in India, delivering globally. Since 2015, we have been offering both prospective and retrospective collections of numerous human biospecimen types along with associated clinical data. We manage our network of over 50 direct contracts with hospitals in India across various disease domains and are always open to establishing new partnerships as needed. With a primary focus on oncology studies, we are fully capable of accommodating your specific inclusion and exclusion criteria, as well as sample processing and aliquoting requirements. Our expertise extends to supporting research projects in various cancer types, including * lung cancer, *breast cancer, *colorectal cancer (#CRC), *kidney cancer, *head & neck cancer, *thyroid cancer, *uterine/endometrial/cervical cancer, and more. To learn more, visit us at www.thebiospecimen.com 📩 Initiate our collaboration by emailing us at sales@thebiospecimen.com or support@thebiospecimen.com #PrecisionMedicine #LungCancerAwarenessMonth #CRO #Biotech #TranslationResearch #pharmaceutical #Researchanddevelopment #cancerresearch #biobank